# Sandostatin LAR (octreotide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				

MALE FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_\_

FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

#### PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_

### AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_\_\_

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
<b>REQUESTOR</b> (if different than prescriber):	OFFICE CONTACT PERSON:		

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



URGENT

## Sandostatin LAR (octreotide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 📃 NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
<ul> <li>Acromegaly</li> <li>Carcinoid tumor</li> <li>Chemotherapy induced diarrhea</li> <li>Chylous ascites</li> <li>Vasoactive intestinal peptide tumors (VIF</li> <li>Other Diagnosis</li> </ul>	-			
	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
PRIOR AUTHORIZATION. For acromegaly, answer the following:				
	adequate response to surgery and/or ra	diotherapy? 🗆 Yes 🗆 No		
Is this a request for initial therapy?				
Is the patient a candidate for either surgery or radiotherapy?*  Yes  No <i>*If NO, please submit documentation.</i>				
For <u>carcinoid tumors</u> , answer the following: Does the patient have severe diarrhea/flushing episodes? Yes D No				
For <u>chemotherapy induced diarrhea</u> , a Has the patient had a documented ina <i>*Please provide documentation</i> .	nswer the following: dequate response to loperamide?*□ Ye	es 🗆 No		
For <u>chylous ascites</u> , also answer the fo Does the patient have a diagnosis of cl	llowing: hylous ascites post-liver transplantatior	? □ Yes □ No		
Does the patient have a documented i alone?*  • Yes  • No *Please provide documentation.	nadequate response to a low-fat diet a	nd/or total parenteral nutrition (TPN)		
Has the patient already received two (	2) months of therapy with Sandostatin	(octreotide)? 🗆 Yes 🗆 No		
For vasoactive intestinal peptide tumors (VIPomas), answer the following:				
Does the patient have profuse watery diarrhea? □ Yes □ No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the				

CAT0215



Revision Date: 08/22/2018

# Sandostatin LAR (octreotide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

### FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

